Swiss Stock Market 2026: Analysis & Forecasts

Key Takeaways

• The KOF Institute (ETH Zurich) expects Switzerland's adjusted real GDP growth of 1.0% for 2026 and 1.7% for 2027
• The Swiss stock market is dominated by defensive heavyweights Roche, Novartis and Nestlé and, unlike international markets, has few major tech stocks
• Smaller Swiss companies are likely to benefit in 2026 from the expected recovery in the eurozone, as they are more cyclically sensitive
• BKW is expected to further improve profits in 2026 thanks to strict cost discipline and hedging activities and remains attractively valued compared to peers
• Analysts see continued attractive profit potential at global stock markets in 2026, although returns are expected to be somewhat lower than in 2025

Macroeconomic environment normalizing

2026 is marked by a gradual normalization of the macroeconomic environment in Switzerland. The KOF Institute at ETH Zurich forecasts adjusted real GDP growth of 1.0% for the current year, with acceleration to 1.7% expected for 2027. A separate meta-analysis comes to a more cautious assessment with 0.5% growth for 2026 (previous forecast: 0.3%), but also sees upward momentum.

The indicators for the manufacturing sector show mixed developments, as documented by the Meta-analysis Konjunktur Schweiz. Despite these uncertainties, market observers believe that the Swiss economy can leverage its defensive position.

Defensive structure characterizes the Swiss stock market

The Swiss stock market differs structurally significantly from international stock exchanges. The three heavyweights Roche, Novartis and Nestlé dominate the domestic stock market landscape and give it a distinctly defensive orientation. Another characteristic: the absence of major tech stocks held back the Swiss market during the global tech rally in 2025.

This relative weakness could turn into strength in 2026. In a normalized market environment where defensive quality stocks are in greater demand again, the structure of the Swiss stock market should be an advantage. While analysts observe no euphoria on the Swiss stock market, the overall assessment remains positive.

Eurozone recovery offers opportunities for SMEs

In addition to the major pharmaceutical stocks, smaller Swiss companies are coming into focus. These are more cyclically sensitive and are likely to benefit in 2026 from the expected recovery in the eurozone, as experts from Zurich Cantonal Bank emphasize. The closer integration with the European economy makes these companies more vulnerable to economic fluctuations, but also offers greater growth potential in a phase of economic recovery.

Raiffeisen experts focus on dividend-rich defensive Swiss stocks, Swiss real estate funds and gold. This strategy aims to benefit from the stability of the domestic market while spreading risks.

BKW as an example of attractive valuations

The Bern-based energy company BKW is considered one of the interesting investment targets on the Swiss market. Basel Cantonal Bank expects the company to further improve profits in 2026 – even without a normalization of energy prices. High cost discipline and effective hedging activities are intended to enable this development.

Compared to similar companies, the BKW stock remains attractively valued. The company has an MSCI rating of AAA and is considered a sustainable investment according to Basel Cantonal Bank's criteria. This combination of defensive positioning, solid fundamental basis and sustainable orientation makes the stock attractive for investors focusing on quality and long-term stability.

Moderate profit potential for 2026

Many analysts see continued attractive profit potential at global stock markets in 2026, although returns are expected to be somewhat lower than in 2025. This assessment is based on the assumption that the macroeconomic environment will continue to normalize and extreme market movements will be avoided.

For Swiss investors, this means a differentiated view: while the large defensive stocks offer stability, smaller, cyclically sensitive stocks could benefit from the expected eurozone recovery. The mix of both segments should be key to optimally leveraging the potential of the Swiss stock market in 2026.